Clinical Trial Update: MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial of MSI-1256F (squalamine lactate) in combination with verteporfin for wet age-related macular degeneration was terminated. This status change indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• MSI-1256F (Squalamine Lactate) (squalamine lactate)
• Verteporfin (verteporfin)

Snippet

Sponsor: Genaera Corporation | Conditions: Macular Degeneration | Phase 2 | Status: TERMINATED